NBY vs. EDSA, EQ, CTXR, PHIO, ME, ALLR, AYTU, LIPO, ATHA, and NEUP
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Edesa Biotech (EDSA), Equillium (EQ), Citius Pharmaceuticals (CTXR), Phio Pharmaceuticals (PHIO), 23andMe (ME), Allarity Therapeutics (ALLR), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), and Neuphoria Therapeutics Inc. - Common Stock (NEUP). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs. Its Competitors
Edesa Biotech (NASDAQ:EDSA) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by company insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Edesa Biotech received 27 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 77.78% of users gave Edesa Biotech an outperform vote while only 1.47% of users gave NovaBay Pharmaceuticals an outperform vote.
Edesa Biotech has higher earnings, but lower revenue than NovaBay Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
Edesa Biotech has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Edesa Biotech's return on equity of -233.69% beat NovaBay Pharmaceuticals' return on equity.
In the previous week, Edesa Biotech had 2 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 2 mentions for Edesa Biotech and 0 mentions for NovaBay Pharmaceuticals. Edesa Biotech's average media sentiment score of 1.44 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the media.
Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 985.27%. NovaBay Pharmaceuticals has a consensus price target of $0.85, indicating a potential upside of 34.92%. Given Edesa Biotech's higher probable upside, analysts clearly believe Edesa Biotech is more favorable than NovaBay Pharmaceuticals.
Summary
Edesa Biotech beats NovaBay Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 6/13/2025 by MarketBeat.com Staff
